Validea Detailed Fundamental Analysis

Johnson & Johnson (JNJ) received an 88% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy, which identifies low book-to-market stocks with sustained growth potential. This places JNJ, a large-cap growth stock in the Biotechnology & Drugs sector, as the highest-rated among 22 guru strategies Validea follows. While JNJ passed most of the model's fundamental criteria, it notably failed the Research and Development to Assets test, with the 88% score indicating 'some interest' rather than 'strong interest' based on the strategy's thresholds.

Analysis

Johnson & Johnson (JNJ) scores favorably under Validea's P/B Growth Investor model, achieving an 88% rating based on the strategy developed by academic Partha Mohanram. This model identifies low book-to-market stocks with strong underlying fundamentals indicative of sustained growth. The 88% score, while high, signifies 'some interest' rather than the 'strong interest' typically associated with scores above 90%. JNJ, a large-cap stock in the Biotechnology & Drugs industry, passed eight of the nine fundamental tests, demonstrating strength in key areas such as Return on Assets (ROA), Cash Flow from Operations to Assets, and stable variance in both ROA and Sales. However, the analysis reveals a notable weakness, as JNJ failed the 'Research and Development to Assets' criterion. This specific failure is a critical data point for a company in the biotech and pharmaceutical space, where R&D is a primary driver of future product pipelines and long-term growth.

Key Decisions for Investors

• Given the strong 88% rating and JNJ's passing marks on multiple cash flow and asset return metrics, investors may see this as a confirmation of the stock's fundamental health as a large-cap growth holding.
• The failure on the 'Research and Development to Assets' metric warrants specific diligence; investors should scrutinize JNJ's R&D spending relative to its peers and its own historical levels to assess the potential risk to its long-term innovation pipeline.
• Considering the score is just shy of the 90% 'strong interest' threshold, a prudent approach could be to hold or initiate a position while monitoring for improvements in R&D metrics or other catalysts that could elevate its growth profile further.